Combination treatment with glecaprevir plus pibrentasvirproduces a sustained virological response in more than 90 percent of hepatitis C virus (HCV)-infected patients who previously failed direct-acting antiviral (DAA) treatments, regardless of liver fibrosis stage, a study has shown.
A recent study has shown that the short-term efficacy of tenofovir disoproxil fumarate (TDF) is superior to entecavir (ETV) for the treatment of acute-on-chronic-liver failure (ACLF) due to reactivation of chronic hepatitis B (CHB).
Mycophenolate mofetil is well tolerated and highly effective in the second-line treatment of patients with autoimmune hepatitis (AIH), although response is greater in those who initiated treatment due to intolerance to standard therapy than in those with nonresponse, according to a systematic review and meta-analysis.
Faecal bile acids and faecal fat predict clinically relevant diarrhoea and constipation in irritable bowel syndrome (IBS) patients who may require more specific treatment rather than simple symptom management, a study has found.
A subgroup of patients with HBeAg-negative chronic hepatitis B virus (HBV) infection who ceased their long-term nucleotide analogue treatment maintained virological suppression, pointing to a group of patients who may be suitable for treatment cessation, according to a recent study.
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.